{"id":"l50-h12-5-a5","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperuricemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination likely contains a long-acting calcium channel blocker, an angiotensin II receptor blocker, and a thiazide or thiazide-like diuretic. Each component targets different mechanisms of hypertension: vasodilation, renin-angiotensin system inhibition, and sodium/fluid reduction, respectively. The fixed-dose formulation is designed to improve medication adherence and efficacy in patients requiring triple therapy.","oneSentence":"L50/H12.5/A5 is a fixed-dose combination of three antihypertensive agents that work synergistically to reduce blood pressure through multiple pathways.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:18:11.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension in patients requiring triple antihypertensive therapy"}]},"trialDetails":[{"nctId":"NCT01302691","phase":"PHASE3","title":"MK-0954E Study in Participants With Hypertension (MK-0954E-357)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-01","conditions":"Hypertension","enrollment":327},{"nctId":"NCT01299376","phase":"PHASE3","title":"MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-24","conditions":"Hypertension","enrollment":286}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK-0954E"],"phase":"phase_3","status":"active","brandName":"L50/H12.5/A5","genericName":"L50/H12.5/A5","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L50/H12.5/A5 is a fixed-dose combination of three antihypertensive agents that work synergistically to reduce blood pressure through multiple pathways. Used for Hypertension in patients requiring triple antihypertensive therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}